Adamis Pharmaceuticals

Adamis Pharmaceuticals EBIT per Share

Delisted

The EBIT per Share of Adamis Pharmaceuticals (ADMP) as of Nov 15, 2026 is -11.70 USD. In the previous year, EBIT per Share was -16.23 USD — a change of -27.95% (higher).

EBIT per Share

-11.70USD

YoY

-27.95%

Last updated:

EBIT per Share of Adamis Pharmaceuticals is 2022 -11.70 USD. EBIT per Share of Adamis Pharmaceuticals was 2021 -16.23 USD. It decreases by -27.95% higher compared to the previous year.

The Adamis Pharmaceuticals EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2019
-32.87 USD
Jan 1, 2020
-0.40 USD
Jan 1, 2021
-16.23 USD
Jan 1, 2022
-11.70 USD
Jan 1, 2023 (e)
-4.92 USD
Jan 1, 2024 (e)
3.15 USD
Jan 1, 2025 (e)
1.75 USD
Jan 1, 2026 (e)
0.99 USD
The Adamis Pharmaceuticals EBIT per Share history
YEAREBIT per ShareYoY
est0.99USD-43.40%
est1.75USD-44.51%
est3.15USD-164.09%
est-4.92USD-57.94%
-11.70USD-27.95%
-16.23USD+3,991.78%
-0.40USD-98.79%
-32.87USD-43.62%
-58.30USD+8.18%
-53.89USD-34.21%
-81.91USD+14.67%
-71.43USD+9,214.74%
-0.77USD-97.70%
-33.41USD-42.41%
-58.01USD+4,924.26%
-1.15USD-98.23%
-65.20USD-34.69%
-99.83USD+13,151.88%
-0.75USD-99.90%
-728.66USD+2,649.34%
-26.50USD-98.74%
-2,111.60USD-83.86%
-13,079.00USD+10,971.77%
-118.13USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Adamis Pharmaceuticals Stock analysis

What does Adamis Pharmaceuticals do? Adamis Pharmaceuticals Corp is a biotechnology company based in the USA that specializes in the development of pharmaceuticals and medical devices. The company was founded in 2006 and is headquartered in San Diego, California. History: Adamis Pharmaceuticals was founded by Dr. Dennis J. Carlo, an experienced pharmaceutical executive with over 35 years of industry experience. The company initially focused on the development of therapeutics for the treatment of allergies and respiratory diseases. Over the years, the company has expanded its portfolio and specialized in the development of drugs for the treatment of anaphylaxis, asthma, and prostate cancer, as well as medical devices for drug delivery. Business model: Adamis Pharmaceuticals focuses on the development of novel drugs and medical devices that can improve patients' lives. The company seeks opportunities to meet unmet medical needs in existing therapy areas. Adamis collaborates closely with leading medical institutions and research facilities to develop and market a portfolio of innovative products. Various divisions: The company has various divisions, including: 1. Allergy/Respiratory: Adamis Pharmaceuticals has developed a broad portfolio of therapeutic agents for the treatment of allergies and respiratory diseases. The company has also developed a patented device called Symjepi, which is used to treat anaphylaxis, a life-threatening allergic reaction. This device also allows untrained individuals to self-treat in an anaphylaxis situation. 2. Oncology: Adamis Pharmaceuticals has developed a novel drug called TeloBlast®, which is used to treat prostate cancer. TeloBlast® targets telomerase, which is upregulated in many types of cancer. The company intends to develop additional drugs for the treatment of cancer in the future. 3. CNS: Adamis Pharmaceuticals has also developed innovative drugs for the treatment of CNS (central nervous system) disorders. The company plans to bring several new drugs for the treatment of neurological disorders to the market by 2022. 4. Medical devices: Adamis Pharmaceuticals has developed a range of patented medical devices, including the ZIM high-pressure injection pump, which allows doctors and nurses to administer medications quickly and accurately. Products: Adamis Pharmaceuticals' products include: 1. Symjepi: A patented device for the treatment of anaphylaxis. 2. TeloBlast®: A novel drug for the treatment of prostate cancer. 3. ZIM high-pressure injection pump: A patented medical device for drug administration. 4. Fluticasone/Salmeterol: An inhalable combination drug for the treatment of asthma and COPD (chronic obstructive pulmonary disease). Adamis Pharmaceuticals is an innovative biotechnology company specializing in the development of pharmaceuticals and medical devices. The company aims to meet unmet medical needs and improve patients' lives. With a broad portfolio of products and a strong commitment to research and development, Adamis Pharmaceuticals is well positioned to continue growing in the future. Adamis Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Adamis Pharmaceuticals stock

EBIT per Share of Adamis Pharmaceuticals is -11.70 USD in 2022.

EBIT per Share of Adamis Pharmaceuticals changed from -16.23 USD to -11.70 USD, representing a -27.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Adamis Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Adamis Pharmaceuticals

All Key Metrics — Adamis Pharmaceuticals